CRISPR Therapeutics
CRSP
CRSP
174 hedge funds and large institutions have $1.09B invested in CRISPR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0.64% less ownership
Funds ownership: 39.84% → 39.2% (-0.64%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
66% less call options, than puts
Call options by funds: $29.7M | Put options by funds: $86.8M
Holders
174
Holding in Top 10
4
Calls
$29.7M
Puts
$86.8M
Top Buyers
| 1 | +$37.1M | |
| 2 | +$23.2M | |
| 3 | +$23M | |
| 4 |
Two Sigma Advisers
New York
|
+$19.6M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$13.3M |
Top Sellers
| 1 | -$81.9M | |
| 2 | -$58.6M | |
| 3 | -$38.2M | |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$21.8M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$10.4M |